Pathologically, an upregulation of EZH2, as observed in many different types of cancers, can essentially contribute to chemoresistance of CRC virtually through promoting cancer stem cell maintenance by modulating major intestinal stem cell renewal pathways such as Wnt/β-catenin and Hedgehog [83]. This evidence concerns the gene EZH2 and colorectal carcinoma.